CD19 and neoplasm: FT596, co-expressing hnCD16 and a CD19-scFv-CAR (hnCD16 + anti-CD19 + IL-15RF) showed potent multi-antigen targeting activity in combination with anti-CD20 mAb against both CD19+ and CD19− tumors in preclinical in vivo studies, with enhanced tumor cell clearance by the multiplexed CAR compared to primary CD19-CAR-T cells [222].